Cardiac Wire #40
The Heart & ADHD Meds | Rethinking HDL-CRead the latest issue
Cardiovascular Disease December 1, 2022
ADHD Meds & Cardiovascular Disease December 1, 2022
New findings suggest ADHD medications — which have raised concerns about CVD risk — are safe for the heart.
Cardiology Pharmaceuticals November 28, 2022
FDA Warns 7 Supplement Companies for Illegally Claiming CV Benefits November 28, 2022
Just weeks after results from the SPORT trial showed no cholesterol benefit from common heart supplements, the FDA has issued warning letters to seven companies for illegally selling dietary supplements that claim to cure, treat, mitigate, or prevent cardiovascular disease.
Cardiology Pharmaceuticals November 21, 2022
Aprocitentan: The New Antihypertensive on the Block November 21, 2022
Aprocitentan has proved itself a promising new agent for blood pressure control. In the PRECISION trial, aprocitentan lowered both office and 24-hour ambulatory BP among people with resistant hypertension.
Surgeries & Interventions November 17, 2022
Cryoablation as a First-Line AFib Therapy November 17, 2022
Cryoablation outperforms antiarrhythmic drugs as a first-line defense against AFib.
Cardiology Pharmaceuticals November 14, 2022
SPORT: Statins Obliterate OTC Heart Supplements November 14, 2022
Six widely used dietary supplements promoted for improving heart health – including brands of fish oil, cinnamon, garlic and turmeric – were not as effective as rosuvastatin at lowering “bad” cholesterol more after 28 days of use.
Cardiology Pharmaceuticals November 10, 2022
Amgen’s Olpasiran Slashes Lp(a) Levels November 10, 2022
The Ocean(a)-DOSE trial made a splash at AHA this year, providing new insight into olpasiran’s potential to reduce Lp(a) levels in patients with ASCVD. In the phase 2 trial, 75 mg or more of the Amgen siRNA therapy delivered at least every three months basically obliterated Lp(a) levels.
Artificial Intelligence November 7, 2022
CW Q&A: Us2.ai’s Strain Analysis Feature￼ November 7, 2022
In this Cardiac Wire Q&A, we sat down with Us2.ai president Yoran Hummel to discuss Us2.ai’s soon-to-be-released automated strain analysis feature.
Cardiology Business November 2, 2022
J&J to Buy Abiomed in $16.6B Deal November 2, 2022
Johnson & Johnson has struck a deal to buy Impella heart pump manufacturer Abiomed for $16.6B, expanding its cardiovascular care portfolio.
Cardiac Imaging October 31, 2022
CW Q&A: Cleerly’s Image Transfer Solution October 31, 2022
We sat down with Cleerly CTO Nick Nieslanik to learn about how Cleerly is tackling the image transfer problem with their new solution, Proxy.
Surgeries & Interventions October 26, 2022
Persistent AFib Breakthrough October 26, 2022
The debate around persistent AFib treatment has continued among electrophysiologists for decades. Contrary to an existing evidence base that shows additional ablation beyond PVI adds nothing, this RCT found that electrically isolating areas of low-voltage did improve AFib suppression.
Surgeries & Interventions October 21, 2022
Abiomed’s Impella Achievements October 21, 2022
Abiomed is celebrating a string of Impella achievements this month, including a new FDA clearance, favorable study results, and, perhaps most importantly, the final wrap-up of Impella’s post-approval studies.
Artificial Intelligence October 19, 2022
HeartFlow Adds Plaque and RoadMap Analysis October 19, 2022
HeartFlow announced the FDA clearance of its new Plaque and RoadMap Analysis AI solutions, making it the “first and only” company to non-invasively assess CAD using anatomy, physiology, and plaque data from coronary CTA exams.
Cardiology Pharmaceuticals October 13, 2022
COVID Drug Paxlovid Interacts with Heart Medications October 13, 2022
A review paper in JACC warns that the COVID antiviral Paxlovid may interact with common heart medications, potentially complicating treatment options.
Cardiology Pharmaceuticals October 12, 2022
Merck’s $11B Acceleron Merger is Paying Off October 12, 2022
Merck just announced that its pulmonary arterial hypertension drug candidate \delivered positive results in a pivotal Phase 3 clinical trial, potentially paving the way for a multibillion-dollar therapeutic and new hope for PAH patients.
Guidelines October 9, 2022
Challenging the Salt Restriction Norm October 9, 2022
A new study challenges the routine practice of restricting salt consumption in acute heart failure cases.
Cardiology Pharmaceuticals October 5, 2022
SGLT2i: A Universal Heart Failure Solution? October 5, 2022
Insights from the present study provide practical evidence to substantiate the initiation of SGLT2 inhibitors during or right after a hospitalization for heart failure.
Physician Reimbursements September 30, 2022
Plaque AI’s Reimbursement Milestone September 30, 2022
The small list of cardiac imaging AI solutions to earn Medicare reimbursements just got bigger, following CMS’ move to add an OPPS code for AI-based coronary plaque assessments. That represents a major milestone for Cleerly, who filed for this code and leads the plaque AI segment, and it marks another sign of progress for the business of imaging AI.
Cardiology Pharmaceuticals September 28, 2022
Deprescribing Aspirin September 28, 2022
For people on warfarin, discontinuing aspirin use may significantly reduce bleeding events without compromising thrombotic risks.
Surgeries & Interventions September 23, 2022
Aggressive LDL Reduction Strategy September 23, 2022
A new study shows aggressive in-hospital PCSK-9 therapy (plus statins) for heart attack patients would likely mean fewer deaths and cardiovascular events.
Surgeries & Interventions September 21, 2022
Renal Denervation’s Comeback September 21, 2022
While previous studies may have fallen short and more research might be needed, physicians and regulators can have renewed confidence that Medtronic’s Symplicity system and ReCor’s Paradise device lower blood pressure.
Preventive Cardiology September 15, 2022
Is HFpEF an Exercise Deficiency Syndrome? September 15, 2022
Thinking of HFpEF as an exercise deficiency syndrome will help physicians better understand the condition, recognize risk earlier, and most importantly, provide a clear path to prevention.